Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | NCK1 | P16333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427493 | 0.85 | NOS3 (0.32) | NOS3NOS2NOS1PIM1PIM2 | |
| SCHEMBL24427783 | 0.78 | KDM4E (0.35) | KDM4EHPGDSMN1; SMN2POLB | |
| SCHEMBL24427865 | 0.74 | KDM4E (0.33) | KDM4EHPGDSMN1; SMN2POLB | |
| SCHEMBL24427332 | 0.73 | TLR9 (0.42) | NOS3NOS2KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL24427823 | 0.73 | PIM2 (0.39) | NOS3NOS2NOS1PIM1PIM2 | |
| SCHEMBL17832297 | 0.72 | SLC9A1 (0.36) | NOS3NOS2NOS1PIM1PIM2 | |
| SCHEMBL24427863 | 0.72 | KDM4E (0.31) | KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL17832298 | 0.71 | KDM4E (0.42) | KDM4EHPGDSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL24427630 | 0.70 | SLC9A1 (0.35) | NOS3NOS2NOS1PIM1PIM2 | |
| SCHEMBL24427511 | 0.69 | MAPK14 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11566027-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-20210009586-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10815233-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3702357-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20200140435-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10550119-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20190352304-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
| US-10407426-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3231803-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016093285-A1 | DIHYDROINDOLIZINONE DERIVATIVE | 小野薬品工業株式会社 | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-10815233-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-20190352304-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-20200140435-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-10407426-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | TFPI, F2, TFPI2 | NOS3 130/4885NOS2 82/4885NOS1 50/4885 |
| US-20210009586-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | NOS3 3789/4885NOS2 2771/4885NOS1 1815/4885 |
| US-11566027-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
| US-10550119-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | NOS3 151/4885NOS2 121/4885NOS1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.